Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients

Profilin potentiates chemotherapeutic agents mediated cell death via suppression of NF-κB and upregulation of p53

(2016) Adeel H. Zaidi et al.   APOPTOSIS

Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma

(2016) Xiaobing Miao et al.   EXPERIMENTAL CELL RESEARCH

Rho GTPases: Anti- or pro-neoplastic targets?

(2016) I Zandvakili et al.   ONCOGENE

The role of ribosomal proteins in the regulation of cell proliferation, tumorigenesis, and genomic integrity

(2016) Xilong Xu et al.   Science China-Life Sciences

Increased nucleophosmin expression is a strong predictor of recurrence and prognosis in patients with N0M0 upper tract urothelial carcinoma undergoing radical nephroureterectomy

(2016) Harutake Sawazaki et al.   WORLD JOURNAL OF UROLOGY

Ribosomal protein L34 promotes the proliferation, invasion and metastasis of pancreatic cancer cells

(2016) Feng Wei et al.   Oncotarget

Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment

(2015) Felicitas Hitz et al.   ANNALS OF HEMATOLOGY

Nano-mechanical Reinforcement in Drug-Resistant Ovarian Cancer Cells

(2015) Young Ho Seo et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Homoharringtonine binds to and increases myosin-9 in myeloid leukaemia

(2015) Ting Zhang et al.   BRITISH JOURNAL OF PHARMACOLOGY

Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation

(2015) M. H. Kim et al.   EMBO JOURNAL

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

(2015) Rosalba Camicia et al.   Molecular Cancer

Expression of RAP1B is associated with poor prognosis and promotes an aggressive phenotype in gastric cancer

(2015) YA YANG et al.   ONCOLOGY REPORTS

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma

(2015) J. R. Devlin et al.   Cancer Discovery

Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?

(2015) Elisa Brighenti et al.   Oncotarget

Dissecting the Mechanisms of Doxorubicin and Oxidative Stress-Induced Cytotoxicity: The Involvement of Actin Cytoskeleton and ROCK1

(2015) Lei Wei et al.   PLoS One

Prognostic Significance of 14-3-3γ Overexpression in Advanced Non-Small Cell Lung Cancer

(2014) Pritsana Raungrut et al.   Asian Pacific Journal of Cancer Prevention

Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer

(2014) L. Zhou et al.   Clinical & Translational Oncology

RecurrentRHOAmutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols

(2014) Marius Rohde et al.   GENES CHROMOSOMES & CANCER

Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma

(2014) Jagan R. Muppidi et al.   NATURE

Identification of up- and down-regulated proteins in doxorubicin-resistant uterine cancer cells: Reticulocalbin-1 plays a key role in the development of doxorubicin-associated resistance

(2014) Eugenie Wong Soon May et al.   PHARMACOLOGICAL RESEARCH

Heat Shock Protein 60 Overexpression Is Associated with the Progression and Prognosis in Gastric Cancer

(2014) Xiao-shan Li et al.   PLoS One

Actin is required for cellular death

(2013) Dariusz Grzanka et al.   ACTA HISTOCHEMICA

Physiological roles of Rho and Rho effectors in mammals

(2013) Dean Thumkeo et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods

(2013) Yiping Liu et al.   MEDICAL ONCOLOGY

Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy

(2013) P. Godwin et al.   Frontiers in Oncology

Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics

(2012) Arun Kanakkanthara et al.   Anti-Cancer Agents in Medicinal Chemistry

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

(2012) Yibin Yang et al.   CANCER CELL

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

(2012) Megan J. Bywater et al.   CANCER CELL

Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma

(2012) Yuanyuan Ruan et al.   JOURNAL OF CLINICAL INVESTIGATION

Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems

(2012) Oktay Tacar et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

(2010) J. Kikuchi et al.   BLOOD

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Aggressive Lymphomas

(2010) Georg Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ribosomal protein S6 is highly expressed in non-Hodgkin lymphoma and associates with mRNA containing a 5′ terminal oligopyrimidine tract

(2010) P R Hagner et al.   ONCOGENE

Actin reorganization in CHO AA8 cells undergoing mitotic catastrophe and apoptosis induced by doxorubicin

(2010) Grzanka   ONCOLOGY REPORTS

Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases

(2009) Y. Xu et al.   BLOOD

The cytoskeleton and cancer

(2009) Alan Hall   CANCER AND METASTASIS REVIEWS